Medium- to Long-term Outlook

  • Pharmaceuticals Domain

Kyowa Kirin; New Vision toward 2030

Kyowa Kirin will realize the successful creation and delivery of life-changing value that ultimately makes people smile, as a Japan-based Global Specialty Pharmaceutical company built on the diverse team of experts with shared passion for innovation.

  • Make patients smile through dramatic improvements in quality of life by identifying the unmet medical needs of people batting with medical conditions and by creating and supplying new drugs or services that help them overcome those challenges.


Drive rapid growth

  • Maximize the value of global products
  • Establish framework to ensure stable global supplies
  • Build a drug pipeline to drive growth beyond 2025
  • Launch services that go beyond pharmaceuticals
  • Foster a corporate culture suited to global business development


Strategies of Kyowa Kirin

  • 2021-2025年中期経営計画の概要

Market environment

In recent years, there have been profound changes seen in the environment surrounding the pharmaceutical industry, such as the promotion of measures to curb medicine costs, decreases in pharmaceutical-related spending due to the promotion of the use of generic medicine, and an increase in both costs and complexity when it comes to the development of new pharmaceuticals. Meanwhile, there have also been moves to expand upon systems involving the assessment of innovations (such as the emergence of a priority review system for new pharmaceutical drugs) as well as moves involving the provision of support for the development of new drug discovery methods which enable innovative treatments through advances in science and technology. Innovative pharmaceuticals which address unmet medical needs are still being waited on across the globe. New medical needs have also been emerging as drastic changes take place in the entire social environments, such as the advancement and entrenchment of digital technologies and the diversification of customer contact points.
Such an environment means that research-oriented pharmaceutical companies are being required to respond to environmental changes with a sense of urgency.

As a global company, Kyowa Kirin strives to demonstrate teamwork which extends across organizational boundaries, based on the company’s shared sense of values centered on Commitment to Life. At the same time, the company is striving to foster a corporate culture befitting of a Japan-based Global Specialty Pharmaceutical Company. The company also aims at contibuting to the health and well-being of people around the world by faithfully fulfilling its corporate social responsibilities, including transparency, fairness, compliance, and coexistence with society, as well as at creating life-changing value by leveraging its advanced technological capabilities.
In 2021, the company announced its 5-year Medium-Term Business Plan with 2025 being the final fiscal year, along with its new vision toward 2030. In 2022, the second year of the Medium-Term Business Plan, Kyowa Kirin will continue to strengthen its foundation as a Global Specialty Pharmaceutical Company and deliver global strategic products to the world. By identifying unmet medical needs and creating and delivering new pharmaceuticals and services to address those needs, Kyowa Kirin aims to be a company able to continuously create life-changing value which puts smiles on the faces of those confronting illness. The company will also continue to promote CSV management which serves to increase its corporate value and earn the trust of society through the creation of new value.

Kyowa Kirin Website


Developing unique pharmaceuticals to bring relief to patients around the world

In accordance with its CSV Commitment in the field of health and well-being, the Kirin Group is working to continuously create ground-breaking new drugs and promote advancements in medical treatments. In line with that commitment, Kyowa Kirin has set the goal of marketing at least three new independently developed pharmaceutical products in over 50 countries.

Improving quality of life of patients around the world

The corporate philosophy of Kyowa Kirin, which conducts the Kirin Group’s medical business, is to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. Under this philosophy, we are focusing research and development efforts on the four key areas of nephrology, oncology, immunology/allergy, and the central nervous system leveraging our cutting-edge biotechnology anchored in antibody technology.

Pharmaceuticals for Worldwide Markets

Kyowa Hakko Kirin Group provides high-quality products and services in the pharmaceutical and biochemical fields to contribute to the health and well-being of people around the world.
At the Group's core is Kyowa Hakko Kirin (KHK), a rapidly evolving global specialty pharmaceutical company (GSP). KHK develops innovative ethical drugs, driven by state-of-the-art biotechnologies, focusing on nephrology, oncology, immunology/allergy, and neurology. Our clinical pipeline and product portfolio contain four main modalities: next-generation therapeutic antibodies, new types of small molecule drugs, nucleic acid drugs, and regenerative therapeutics.

Related Information